Abstract
Lymphokine-activated killer (LAK) activity of peripheral blood mononuclear cells (PBMC) from 33 patients with hepatocellular carcinoma was significantly decreased compared with that of healthy volunteers. There was less LAK activity in PBMC from patients with larger tumours (5 cm or more in diameter) than in patients with smaller tumours (under 5 cm in diameter). In 8 out of 20 patients with larger tumours there was none or little LAK activity. Flow cytometry revealed that the percentage of Leu11b+ cells in PBMC was lower in patients than in normal volunteers, and was lowest in patients with larger tumours. 10 patients with hepatocellular carcinoma were treated with intratumoral injection of OK432. LAK activity was enhanced after treatment in 7 cases, and the percentage of Leu11b+ cells was increased. Enhancement of LAK activity in response to OK432 was more significant in patients with smaller rather than larger tumours. Of the 7 high LAK responders, 4 showed 50–100% tumour regression at 6–9 weeks after injection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
